

Zhang Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9706059/publications.pdf>

Version: 2024-02-01

18
papers

329
citations

933447

10
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

424
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 25.	8.6	6
2	A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished. <i>Cancers</i> , 2022, 14, 390.	3.7	9
3	Naples Prognostic Score as a novel prognostic prediction tool in video-assisted thoracoscopic surgery for early-stage lung cancer: a propensity score matching study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 3679-3697.	2.4	30
4	Systemic Inflammation Score as a Novel Prognostic Indicator for Patients Undergoing Video-Assisted Thoracoscopic Surgery Lobectomy for Non-Small-Cell Lung Cancer. <i>Journal of Investigative Surgery</i> , 2021, 34, 428-440.	1.3	21
5	CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for <i>FGFR1</i> -Amplified Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3121-3133.	0.9	12
6	Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5-deoxy-5-fluorocytidine (5-DFCR). <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 138.	8.6	9
7	Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. <i>Cell Death and Disease</i> , 2021, 12, 406.	6.3	10
8	Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in <i>KRAS</i> mutant cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e13193.	6.9	11
9	ACSL3 ^{hi} PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. <i>Science Advances</i> , 2020, 6, .	10.3	27
10	Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2020, 12, 2310.	3.7	15
11	Is liposomal bupivacaine superior to standard bupivacaine for pain control following minimally invasive thoracic surgery?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 199-203.	1.1	1
12	Serum uric acid to lymphocyte ratio: A novel prognostic biomarker for surgically resected early-stage lung cancer. A propensity score matching analysis. <i>Clinica Chimica Acta</i> , 2020, 503, 35-44.	1.1	10
13	CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 661-672.	4.1	26
14	HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. <i>Oncogenesis</i> , 2019, 8, 45.	4.9	38
15	Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2019, 11, 1502.	3.7	27
16	Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score matching study. <i>ANZ Journal of Surgery</i> , 2019, 89, E507-E513.	0.7	31
17	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019, 38, 622-636.	5.9	37
18	Single-incision versus multiport video-assisted thoracoscopic surgery in the treatment of lung cancer: a systematic review and meta-analysis. <i>Acta Chirurgica Belgica</i> , 2018, 118, 85-93.	0.4	8